Tag

SARS-CoV-2

CR2O to manage First-in-Human trial with Dyadic’s SARS-CoV-2-S-RBD vaccine candidate DYAI-100

CR2O is proud to announce today it will manage and further support the clinical and preclinical development of DYAI-100, Dyadic’s C1 produced SARS-CoV-2-S-RBD vaccine candidate. The first-in-human trial with DYAI-100...
Read More

H2020 awards contract to develop a monoclonal antibody against COVID-19

The EU Research and Innovation programme HORIZON 2020 has awarded a contract worth up to 3 million euro’s to a European consortium led by ErasmusMC in collaboration with Harbour Antibodies...
Read More